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Objectives: Poor adherence to antipsychotics in schizophrenia is common and 
associated with increased hospitalization risk, a key driver of increased costs of care. 
The objective was to evaluate the effectiveness of a patient-assisted medication 
adherence program (PAMAP) on psychiatric hospitalization rates among schizo-
phrenia patients treated with long-acting injectable risperidone (RLAI). MethOds: 
Between 2009-2010, patients aged 18-65 years meeting DSM-IV criteria for schizo-
phrenia and treated with RLAI were recruited from 36 centers in France and followed 
for 1 year. The PAMAP consisted of calling patients 48 hours prior their scheduled 
RLAI injections and within 3 days of a missed appointment. Adherent centers 
applied PAMAP to ≥ 50% of injections. Adherent patients received ≥ 80% of their 
injections within 5 days of the scheduled date. Otherwise, patients and centers 
were non-adherent. Poisson regression was used to derive rate ratios (RR) compar-
ing psychiatric hospitalization rates among adherent and non-adherent patients 
and centers. Propensity scores were used to derive adjusted RRs. Results: Of 506 
recruited patients, 95.7% were followed up to 1 year (average age: 38.7; 64.6% males; 
60.4% hospitalized in the previous year). Overall hospitalization rate over follow-up 
was 32.5 per 100 person-years. Fifteen centers treating 243 patients and 21 centers 
treating 263 patients were adherent and non-adherent, respectively. Lower hospitali-
zation rates were associated with PAMAP (crude RR: 0.64 [95% CI: 0.44-0.93]; adjusted 
RR: 0.78 [95% CI: 0.47-1.27]). Nearly 75% of patients were adherent but adherence 
was not associated with disease severity nor with reduced hospitalization rates. 
The effect of PAMAP on hospitalizations rates was greater among non-adherent 
(adjusted RR: 0.45 [95% CI: 0.16-1.28]) than adherent patients (adjusted RR: 0.88 [95% 
CI: 0.51-1.53]). cOnclusiOns: Adherence among schizophrenia patients partak-
ing in a PAMAP for RLAI was high. PAMAP may reduce psychiatric hospitalization 
risk for schizophrenia patients with problems adhering to long-acting injectable 
antipsychotics treatment regimens.
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Objectives: Cannabis is the most commonly used illicit substance in the United 
States. Usage rates have climbed in recent years, underscoring the need for knowl-
edge regarding the effects of cannabis use on factors associated with chronic health 
problems, such as heart disease and diabetes mellitus. Some studies suggest that 
cannabis use is associated with improvements in weight, BMI, and insulin resist-
ance. MethOds: Data on 4,267 persons from Continuous National Health and 
Nutrition Examination Survey (NHANES) from 2005 to 2010 was used to explore 
the relationship between cannabis use and factors of metabolic syndrome, includ-
ing fasting insulin, glucose, insulin resistance, hemoglobin A1c, triglycerides, HDL 
cholesterol, BMI, waist circumference, and blood pressure. These relationships were 
first estimated with ordinary least squares (OLS) models. Next, instrumental vari-
ables (IV) methods were utilized to test and account for the potential endogeneity 
of cannabis use in the models. The first IV models used sexual behavior variables 
as instruments for past and current use of cannabis. The second used past cannabis 
use as an instrument for current use. Results: OLS models show lower fasting 
insulin, insulin resistance, BMI, and waist circumference in past cannabis users 
compared to individuals who reported never having used cannabis. In the first 
IV model, the coefficients on cannabis use are mostly non-significant. When past 
cannabis use is an instrument for current use, the results for fasting insulin, insulin 
resistance, and fasting glucose are significant in the opposite direction from the 
OLS results. Durbin-Watson-Hausman tests provide evidence of endogeneity of can-
nabis use for some outcomes. cOnclusiOns: Models of the relationship between 
cannabis and health should account for endogeneity. Results of two-stage least 
squares estimation are inconsistent with OLS results, challenging the robustness 
of findings that indicate a positive relationship between cannabis use and fasting 
insulin, insulin resistance, BMI, and waist circumference.
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Objectives: Newer antidepressants selective serotonin reuptake inhibitors (SSRIs) 
and serotonin norepinephrine reuptake inhibitors (SNRIs) are the most commonly 
prescribed antidepressants. This is due mostly to their better side effect profile when 
compared to older drugs like tricyclic antidepressants (TCAs). However these classes 
are not completely bereft of side effects. Psychosexual dysfunction is a condition 
that occurs commonly among depressed patients. It has been shown to be associ-
ated with antidepressant. The objective of our study is to compare the incidence of 
psychosexual dysfunction between TCAs, SSRIs, and SNRIs. MethOds: We used a 
cohort study design in an administrative claims database (2006-2013 Lifelink claims 
data) to compare the incidence of psychosexual dysfunction in TCAs, SSRIs, and 
SNRIs. Incidence was reported per 10,000 person-years. The Cox proportional hazard 
model was used to assess the risk of adverse events while adjusting for potential 
confounders. Results: A total of 269489 patients with an incident prescription 
for a TCA, SSRIs or SNRIs were identified and met the study inclusion criteria. They 
constituted a total of 682,657 person years. The unadjusted hazard ratio of incidence 
of psychosexual dysfunction in patients on SNRIs compared to SSRIs was 1.625 
(1.506-1.755). The results were consistent after adjusting for various covariates using 
the Cox proportional hazards model. The hazard ratio for the full model was 1.429 
(1.323-1.545) and for the reduced model with covariates identified using stepwise 
regression was 1.431(1.325-1.546). The directionality of covariates adjusted for in 
the analysis was consistent with current literature. cOnclusiOns: SNRIs were 
associated with a greater risk of psychosexual dysfunction than SSRIs.
at week 6; the functional remission rate was similar for participants receiving lur-
asidone 20-60 mg and lurasidone 80-120 mg group (41.1% and 40.6%, respectively). 
Controlling for baseline SDS total score and study center, the adjusted odds ratio 
for functional remission among participants receiving lurasidone versus placebo 
was 3.96 (p< 0.01, 95% CI [1.72, 9.13]) in the 20-60 mg lurasidone group and 2.46 
(p= 0.52, 95% CI [1.12 - 5.43]) in the 80-120 mg lurasidone group. cOnclusiOns: 
This post-hoc analysis of a lurasidone pivotal trial showed statistically significant 
improvement in functional remission within 6-week study duration among patients 
with bipolar depression treated with lurasidone compared to placebo.
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Objectives: The current study aimed at assessing the impact of LAIs versus OAs 
on hospitalizations among patients with schizophrenia by conducting a thorough 
systematic review of studies with different study designs and performing a meta-
analysis. MethOds: Using the PubMed database and major psychiatric conference 
proceedings, a systematic literature review for 01/2000–07/2013 was performed to 
identify English-language studies evaluating schizophrenia patients treated with 
atypical antipsychotics. Studies reporting hospitalization rates as a percentage of 
patients hospitalized or as the number of hospitalizations per-person per-year were 
selected. A meta-analysis of the percentage decrease in hospitalization rates from 
baseline during treatment was conducted as a primary analysis. The secondary anal-
ysis was a meta-analysis of the absolute rate of hospitalization during follow-up. 
Pooled treatment-effect estimates were calculated using random-effect models. To 
account for differences in patient and study-level characteristics between studies, 
meta-regression analyses were used. Subset analyses further explored the hetero-
geneity across study designs. No adjustment was made for multiplicity. Results: 
Fifty-eight studies evaluating 25 arms (LAIs: 13 arms, 4,516 patients; OAs: 12 arms, 
23,516 patients) in the primary analysis and 78 arms (LAIs: 12 arms, 4,481 patients; 
OAs: 66 arms, 96,230 patients) in the secondary analysis were identified. Reduction 
in hospitalization rates for LAIs was 20.7 percentage points higher than that of 
OAs (random-effect estimates: LAIs= 56.2% vs OAs= 35.5%, P= 0.023). Controlling for 
patient and study characteristics, the adjusted percentage reduction in hospitaliza-
tion rates for LAIs was 26.4 percentage points higher than for OAs (95%CI: 3.3-49.5, 
P= 0.027). As for the secondary analysis, no significant difference between LAIs and 
OAs was observed (random-effect estimate: -8.6, 95%CI: -18.1-1.0, P= 0.077). Subset 
analyses across type of study yielded consistent results. cOnclusiOns: Results 
of this meta-analysis including studies with both interventional and non-interven-
tional designs and using meta-regressions, suggest that LAIs significantly reduce 
hospitalization rates for schizophrenia patients compared to OAs.
PMH11
tHE tradEoff bEtwEEn intErnal and ExtErnal validity in coMParing 
tHE EffEctivEnEss of transcranial MagnEtic stiMulation (tMs) witH 
antidEPrEssant drug tHEraPy in tHE trEatMEnt of Major dEPrEssion 
using ProPEnsity scorE MEtHods
Simpson A.N.1, Simpson K.N.1, Bonneh-Barkay D.2, Demitrack M.A.2, Brock D.G.2
1Medical University of South Carolina, Charleston, SC, USA, 2Neuronetics, Inc., Malvern, PA, USA
Objectives: Transcranial magnetic stimulation (TMS) is FDA cleared for use in 
pharmacoresistant depression. Two sham-controlled trials have confirmed its 
efficacy and safety. However, TMS has not been directly compared to pharmaco-
therapy. Propensity score matching was used to compare the effectiveness of TMS 
to pharmacotherapy. Prospectively collected data from a pragmatic study of 305 
patients treated in routine practice with TMS were matched to patients from the 
Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study. MethOds: 
TMS patients were propensity-score matched to STAR*D patients on baseline char-
acteristics using a 1:1 greedy matching algorithm. An unequal drug resistance 
distribution in the two populations allowed only 222 patients to match well on 
the first attempt. A subsequent re-matching of the remaining TMS subjects to the 
full STAR*D control population was performed to produce a complete match. This 
“double-dipping” approach enabled a successful complete match for all 305 TMS 
patients. Results: The matched STAR*D and TMS populations were similar at base-
line. QIDS-SR outcomes at 6 weeks showed that the TMS group had a greater clinical 
improvement (P< 0.0001). At 6-weeks 53% of TMS patients had no or mild depres-
sion versus 38% for STAR*D (p= 0.0023). Sensitivity analysis was used to estimate 
the potential effects of any remaining selection biasing factors, and confirmed an 
unlikely impact on results. cOnclusiOns: The varying distribution of the severity 
of baseline treatment resistance between the TMS and STAR*D populations made it 
impossible to achieve a complete match in the first matching attempt. Subsequent, 
“double-dipping” allowed tight matching on baseline variables. We accepted the 
risk to internal validity posed by the remaining selection bias or confounding and 
the small impact to variability due to non-independence, in exchange for gaining 
an increased external validity for this difficult to match group. Matching hard-to-
match groups requires a trade-off between risks to internal and external validity.
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